Ballard Spahr says the Hikma v. Amarin decision makes it harder for brand-name drugmakers to sue over "skinny label" generics — a shift likely to speed generic competition and lower costs for patients
Related to this article
CMS chief says outcomes-based pay can help patients while finally ending physicians' box-checking frustration.
The 3-part federal plan targets costs, red tape and corporate consolidation across commercial health insurance.
RFK Jr. appoints members to fill a panel that has not met in more than a year, but is influential on primary care.
Reactions from five leading organizations were among thousands of public comments on the draft document.
Physician groups back ACCESS Model but warn CMS against care fragmentation
Top HHS leaders introduce ACCESS model with discussions of patient health, costs and technology.
A Lancet modeling study of 195 medicines estimates the Trump administration's GLOBE and GUARD pricing models could save Medicare up to $11.6 billion in their initial phase — but confidential manufacturer deals could erase nearly 80% of those savings.
Advertisement
Advertisement
Trending on Medical Economics
1
On National Physician Suicide Awareness Day 2026, 71% of physicians say mental health stigma persists
2
Michigan man charged with billing Medicare for psychotherapy never provided; women less likely than men to receive intensive treatment; gambling disorder emergency visits nearly doubled in Ontario — Morning Medical Update
3
59% of health care workers plan to look for a new job in the next year, Harris Poll finds
4
Georgetown report calls for capping hospital prices, reforming prior authorization and curbing medical debt
5